Proactive Investors - Run By Investors For Investors

Botanix Pharmaceuticals advances eczema study faster than expected

The company is developing BTX 1204, a new treatment for eczema.
scientist in lab
The prescription market generates more than US$8 billion in annual sales globally

Botanix Pharmaceuticals Ltd (ASX:BOT) has completed enrolment of its phase Ib atopic dermatitis patient study for treatment BTX 1204.

Notably, the study enrolment was completed in advance of Botanix management’s initial target, underpinned by significant interest from patients in joining the study.

Botanix is developing BTX 1204, a new treatment for mild to moderate atopic dermatitis, also known as eczema.

The company remains on track to release phase Ib results in June quarter of 2018.

Targeting a market worth US$8 billion in annual sales

Atopic dermatitis is a common chronic inflammatory skin disorder and the prescription market generates more than US$8 billion in annual sales globally.

Patients display achronic rash characterised by inflammation and itching with symptoms lasting 14 days or more.

Before the recent approval of Eucrisa® (crisaborole), there had been no new drugs approved for atopic dermatitis for more than 15 years.

Competing treatment has little to no impact on itch

Based on successful phase III studies, Pfizer Inc (NYSE:PFE) acquired the company that developed Eucrisa®  for US$5.2 billion in May 2016.

Notably, clinical studies showed that Eucrisa® had little to no impact on itch, which remains a key unmet need for atopic dermatitis patients.

Potential to move to phase II this year

Following completion of this study, Botanix plans to file an Investigational New Drug (IND) application with the FDA.

This will allow a multicentre phase II safety and efficacy study for BTX 1204 to potentially commence later in December half of this year.

View full BOT profile View Profile

Botanix Pharmaceuticals Ltd Timeline

Related Articles

September 20 2018
Following the disappointment of its DMD treatment over summer, Summit is leveraging its Discuva platform to develop new antibiotics, which doctors are in desperate need of
tumour cells
July 25 2018
Sign-off by the US Food & Drug Administration is considered the "global standard for approval", the company said
Collagen testing
August 17 2018
Since reporting its full-year results on July 10, the AIM-listed shares have rallied over 38% in the past month to 3.65p currently, taking year-to-date gains to a third

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use